Additional Information
has the experience
and resources to
handle complex claims involving prescription medication.
Bextra
In 2001 Bextra joined the then-growing list of Cox-2 Inhibitors on the billion-dollar pain reliever market. Cox-2 Inhibitors are used to treat osteoarthritis, acute pain and painful menstrual cycles.
Initial reports treated drugs like Bextra as miracle drugs, as they seemed to work better than traditional nonsterodial anti-inflammatories (NSADs) like ibuprofen or aspirin. Even better, they provided pain relief without the serious problems from stomach ulcers, including bleeding, that was associated with long-term use.
Unfortunately, Cox-2 Inhibitors were later cited in several studies as significantly increasing the chance of heart attack or stroke in people who have taken the drugs.
On April 7, 2005, the FDA withdrew Bextra from the market.
SimmonsCooper has experience in litigating complex medical matters. We have taken a leadership role in standing up for individuals who have been injured by dangerous or defective drugs and devices and over the last few years have represented thousands of pharmaceutical clients and recovered verdicts and settlements totaling more than $100 million.*
The two other major Cox-2 inhibitors, Vioxx and Celebrex, have also come under much-deserved scrutiny. For a timeline of events related to Bextra, click here.
For more information about how we identify potentially dangerous drugs and to determine a manufacturer’s liability, click here.
* Please note that recovery results vary per client. The recovery amounts in each case reflect the specific facts of that case. Further, recovery amounts in past cases are not a guarantee of future results.
Resources for Clients
United States Food and Drug Administration (FDA) Center for Drug Evaluation and Research
Medline Plus
Medwatch
New England Journal of Medicine
American College of Rheumatology
The Arthritis Foundation
The National Databank for Rheumatoid Diseases
American Heart Institute
American Stroke Association